Laetrile and Related Substances — NCD 137 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 137, the national coverage determination governing laetrile and related substances, effective March 7, 2026. Medicare does not cover laetrile under any circumstances — and this policy update makes that position explicit for billing teams managing cancer-related claims.

Quick-Reference Table

CMS Laetrile Coverage Policy and Medical Necessity Requirements 2026

The CMS laetrile coverage policy under NCD 137 in the Medicare system is absolute: laetrile is not covered. Full stop. There is no clinical scenario, no diagnosis, and no setting where Medicare will reimburse for laetrile or any substance that goes by an equivalent name.

The Centers for Medicare & Medicaid Services bases this on a formal FDA determination. The FDA has concluded that laetrile — and every drug referred to by the terms laetrile, amygdalin, Sarcarcinase, vitamin B-17, and nitriloside — is not generally recognized as safe or effective for any therapeutic use. "Generally recognized" here has a specific legal meaning: it requires consensus among experts qualified by scientific training and experience to evaluate drug safety and effectiveness. That consensus does not exist for laetrile. It never has.

Under §1862(a)(1) of the Social Security Act, Medicare only pays for items and services that are reasonable and necessary for the diagnosis or treatment of illness or injury. Because laetrile fails the FDA's safety and effectiveness standard, it cannot meet the medical necessity threshold under Medicare. No documentation, no physician order, and no prior authorization request will change that. The coverage policy is a hard exclusion.

This matters for oncology billing teams in particular. Laetrile has been used — and in some patient populations continues to be sought — as a cancer treatment or adjunct. Patients who pursue it outside conventional care sometimes return to hospital settings or physician offices where billing teams may encounter claims questions. Know the rule before you need to answer the question.

CMS Laetrile Exclusions and Non-Covered Indications

NCD 137 draws two clean lines. Neither situation is covered, and neither has any exception pathway.

Inpatient hospital stays for laetrile administration. If a patient is admitted to the hospital solely to receive laetrile or any equivalent substance, that stay is not covered by Medicare. The admission itself is the problem — if the purpose is laetrile administration, the entire hospital stay falls outside Medicare's covered benefits. This is not a documentation fix. There is no way to recode or reframe this type of admission to achieve reimbursement.

Laetrile during an otherwise covered hospital stay. This one is trickier in practice. A patient can have a legitimate, covered reason for a hospital admission — a surgical procedure, a covered cancer treatment, a complication requiring inpatient care. If laetrile is then administered during that stay, Medicare will not pay for the laetrile or any services directly tied to its administration. The rest of the covered stay may be billable. But the laetrile component is carved out entirely.

Your billing team should treat laetrile billing the same way you treat any categorically excluded service: identify it, separate it from covered services on the claim, and do not submit it to Medicare. Submitting non-covered services to Medicare without a valid Advance Beneficiary Notice of Noncoverage (ABN) creates compliance exposure. Submitting them knowingly creates a different kind of problem entirely. If your team has any questions about how to handle mixed claims — covered inpatient services alongside laetrile administration — loop in your compliance officer before the effective date of March 7, 2026.

The chemical identity issue in NCD 137 is worth flagging. The policy notes that the terms laetrile, amygdalin, Sarcarcinase, vitamin B-17, and nitriloside have been used interchangeably in the market — but the actual chemical identity of substances sold under these names has varied. That's not a loophole. CMS covers all of these under the same exclusion, regardless of what the product is labeled or how it's marketed to patients.

Coverage Indications at a Glance

CMS Laetrile Billing Guidelines and Action Items 2026

These are not hypothetical steps. They are the specific things your billing team and compliance officer should do before and after March 7, 2026.

CPT, HCPCS, and ICD-10 Codes for Laetrile Under NCD 137

Coverage Status

NCD 137 does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is consistent with the nature of the policy — it is a categorical exclusion, not a code-level coverage determination.

There are no covered codes to list. There are no "covered when criteria are met" codes. The policy applies to any claim that involves laetrile or its equivalent substances, regardless of how the service is coded.

What This Means for Your Coding Team

The absence of specific codes does not give your team flexibility. It means the exclusion is substance-based, not code-based. If the drug administered is laetrile — or amygdalin, or vitamin B-17, or any of the other named equivalents — Medicare does not cover it. The code used to bill it does not change that.

If your billing team runs a code-level claim edit to catch non-covered services, you may not be able to catch laetrile claims through code edits alone. The catch has to happen upstream, at the point of order or administration. Build that into your workflow before the effective date of March 7, 2026.